Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting. J Neurooncol 2025 May;173(1):49-57
Date
03/31/2025Pubmed ID
40163248Pubmed Central ID
PMC12040967DOI
10.1007/s11060-025-04946-wScopus ID
2-s2.0-105001514823 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
PURPOSE: Tumor Treating Fields therapy (TTFields) is an FDA-approved locoregional treatment for patients with newly diagnosed glioblastoma (ndGBM). Previous trial data showed the addition of TTFields to standard TMZ-based therapy to significantly improve overall survival (OS), but real-world data is lacking, particularly with long follow-up duration. Here, we report real-world survival, patterns of progression, and patterns of use for patients for patients with ndGBM treated with or without TTFields.
METHODS: Patients diagnosed with GBM and treated with standard of care therapy at the Medical College of Wisconsin between March 2015-March 2023 were included. Survival outcomes were assessed and compared across groups who received or did not receive TTFields therapy during maintenance treatment. Patients were followed through March 1, 2024.
RESULTS: A total of 208 patients (TTFields: n = 109; No-TTFields: n = 99) were included for analysis. Baseline characteristics were consistent across groups. Median OS and PFS were significantly improved for the TTFields group vs. No-TTFields group (median OS: 21.7 vs. 17.7 months, p = 0.029; median PFS: 12.4 vs. 9.6 months, p = 0.047). Patients treated with TTFields exhibited a higher rate of non-local progression vs. No-TTFields group. Median OS and PFS were each significantly longer for the ≥ 75% usage group compared with < 75% via matched analysis.
CONCLUSION: The results of this study reveal an association between TTFields use and long-term survival benefit, consistent with pivotal trial findings. TTFields use is associated with a higher incidence of non-local patterns of progression, and TTFields device usage ≥ 75% is associated with increased progression-free and long-term survival.
Author List
Riegel DC, Bureau BL, Conlon P, Chavez G, Connelly JMAuthor
Jennifer M. Connelly MD Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Brain Neoplasms
Combined Modality Therapy
Disease Progression
Electric Stimulation Therapy
Female
Follow-Up Studies
Glioblastoma
Humans
Male
Middle Aged
Retrospective Studies
Survival Rate
